US · PRGO · DRUG MANUFACTURERS - SPECIALTY & GENERIC
Perrigo Company plc (PRGO) intrinsic value and stock valuation
$15.94as of 2026-11-21 · Mkt cap 1.84B
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
Perrigo Company plc DCF and intrinsic value
InvestorsCraft values PRGO with the Chepakovich two-stage DCF model — currently rated overvalued. How the model works · Run your own DCF prefilled from PRGO’s statements →
Perrigo Company plc Graham Number
The Graham Number is not defined for negative earnings or book value. Guide · Calculator →
How the business is doing
Fiscal 2011–2025, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Peers
Same-industry companies, ranked by market cap
- Scholar Rock Holding Corporation (SRRK) $48.13
- LivaNova PLC (LIVN) $90.73
- Tarsus Pharmaceuticals, Inc. (TARS) $73.01
- Supernus Pharmaceuticals, Inc. (SUPN) $28.61
- Heartflow, Inc. Common Stock (HTFL) $46.69
- Bausch Health Companies Inc. (BHC) $8.22
- HUTCHMED (China) Limited (HCM) $13.22
- Surgery Partners, Inc. (SGRY) $26.78
Peer comparison
The peer comparison table is shown only to users with a Pro subscription.
Financials
Statements by fiscal year
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $4.25B | $4.37B | $4.66B | $4.45B | $4.14B |
| Operating income | $343.3M | $112.9M | $151.9M | $78.9M | $410.4M |
| Net income | -$-1.43B | -$-171.8M | -$-12.7M | -$-140.6M | -$-68.9M |
| EPSd | -$-10.29M | -$-1.25M | -$-93.87K | -$-1.05M | -$-515.72K |
| Operating cash flow | $238.5M | $362.9M | $405.5M | $307.3M | $156.3M |
| Capital expenditure | -$-93.4M | -$-118.3M | -$-101.7M | -$-96.4M | -$-152.1M |
| Free cash flow | $145.1M | $244.6M | $303.8M | $210.9M | $4.2M |
| Total assets | $8.54B | $9.65B | $10.8B | $11B | $10.4B |
| Total debt | $3.97B | $3.62B | $4.07B | $4.32B | $3.69B |
| Net debt | $3.44B | $3.06B | $3.32B | $3.72B | $1.83B |
| Total equity | $2.94B | $4.32B | $4.77B | $4.84B | $5.15B |
| Cash and short-term investments | $531.6M | $558.8M | $751.3M | $600.7M | $1.86B |
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $4.25B | $4.37B | $4.66B | $4.45B | $4.14B |
| Cost of revenue | $2.76B | $2.83B | $2.98B | $3B | $2.72B |
| Gross profit | $1.49B | $1.54B | $1.68B | $1.46B | $1.42B |
| Research and development expenses | $95.4M | $112.2M | $122.5M | $123.1M | $122M |
| Selling, general and administrative expenses | $526.5M | $1.11B | $1.27B | $1.21B | $1.11B |
| Other expenses | $529.3M | $205M | $131.4M | $43.3M | -$-227.6M |
| Operating expenses | $1.15B | $1.43B | $1.53B | $1.38B | $1.01B |
| Cost and expenses | $3.91B | $4.26B | $4.5B | $4.37B | $3.73B |
| Interest income | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Interest expense | $162.5M | $187.8M | $173.8M | $156M | $125M |
| Depreciation and amortization | $337.5M | $325.9M | $359.5M | $338.6M | $312.2M |
| Ebitda | -$-797.9M | $433M | $525M | $355.5M | $695.9M |
| Operating income | $343.3M | $112.9M | $151.9M | $78.9M | $410.4M |
| Total other income/expenses, net | -$-1.64B | -$-193.6M | -$-160.2M | -$-218M | -$-151.7M |
| Income before tax | -$-1.3B | -$-80.7M | -$-8.3M | -$-139.1M | $258.7M |
| Income tax expense | $104.4M | $80M | -$-3.9M | -$-8.2M | $389.6M |
| Net income | -$-1.43B | -$-171.8M | -$-12.7M | -$-140.6M | -$-68.9M |
| Weighted average shares outstanding | $138.5M | $137.4M | $135.3M | $134.5M | $133.6M |
| Weighted average diluted shares outstanding | $138.5M | $137.4M | $135.3M | $134.5M | $133.6M |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash and short-term investments | $531.6M | $558.8M | $751.3M | $600.7M | $1.86B |
| Net receivables | $612.8M | $642.3M | $739.6M | $697.1M | $652.9M |
| Inventory | $1.15B | $1.08B | $1.14B | $1.15B | $1.02B |
| Total current assets | $2.8B | $2.48B | $2.83B | $2.72B | $3.86B |
| Property, plant and equipment, net | $1.07B | $1.09B | $1.1B | $1.14B | $1.03B |
| Goodwill and intangible assets | $4.41B | $5.75B | $6.52B | $6.78B | $5.15B |
| Long-term investments | $25.4M | $0.00 | $0.00 | $0.00 | $0.00 |
| Total non-current assets | $5.74B | $7.17B | $7.98B | $8.3B | $6.57B |
| Total assets | $8.54B | $9.65B | $10.8B | $11B | $10.4B |
| Accounts payable | $474.5M | $495.2M | $477.7M | $537.3M | $411.2M |
| Short-term debt | $62.3M | $36.4M | $440.6M | $64.6M | $629.8M |
| Deferred revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total current liabilities | $1.01B | $1.04B | $1.59B | $1.11B | $1.59B |
| Long-term debt | $3.91B | $3.58B | $3.63B | $4.26B | $3.06B |
| Deferred revenue, non-current | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total non-current liabilities | $4.59B | $4.28B | $4.45B | $5.06B | $3.69B |
| Capital lease obligations | $163M | $0.00 | $0.00 | $217.9M | $173.3M |
| Total liabilities | $5.6B | $5.33B | $6.04B | $6.18B | $5.27B |
| Common stock | $6.61B | $6.73B | $6.84B | $6.94B | $7.04B |
| Retained earnings | -$-3.68B | -$-2.25B | -$-2.08B | -$-2.07B | -$-1.93B |
| Accumulated other comprehensive income (loss) | $14.1M | -$-162.4M | $10.7M | -$-27M | $35.5M |
| Total equity | $2.94B | $4.32B | $4.77B | $4.84B | $5.15B |
| Total investments | $25.4M | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $3.97B | $3.62B | $4.07B | $4.32B | $3.69B |
| Net debt | $3.44B | $3.06B | $3.32B | $3.72B | $1.83B |
Cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net income | -$-1.4B | -$-171.8M | -$-12.7M | -$-130.9M | -$-68.9M |
| Depreciation and amortization | $337.5M | $325.9M | $359.5M | $338.6M | $312.2M |
| Stock-based compensation | $0.00 | $64.4M | $68.8M | $0.00 | $60.1M |
| Change in working capital | -$-101.1M | -$-74.7M | -$-58.5M | $20M | -$-295.4M |
| Accounts receivable | $30.7M | -$-11.1M | -$-57.1M | $100K | -$-159.7M |
| Inventory | -$-61.1M | $13.7M | $19.4M | -$-76.7M | -$-2.4M |
| Accounts payable | -$-28.7M | $54.2M | -$-65.9M | $100.3M | -$-7.9M |
| Net cash provided by operating activities | $238.5M | $362.9M | $405.5M | $307.3M | $156.3M |
| Investments in property, plant and equipment | -$-93.4M | -$-118.3M | -$-101.7M | -$-96.4M | -$-152.1M |
| Acquisitions, net | $0.00 | $0.00 | $0.00 | -$-1.95B | $1.49B |
| Net cash used for investing activities | -$-75.4M | $78.8M | -$-77.5M | -$-1.96B | $1.28B |
| Common stock issued | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Common stock repurchased | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Dividends paid | -$-159.3M | -$-152.5M | -$-149.7M | -$-142.4M | -$-129.6M |
| Net cash used for financing activities | -$-220.5M | -$-611M | -$-187.2M | $421.6M | -$-178.7M |
| Net change in cash | -$-27.2M | -$-192.5M | $150.6M | -$-1.26B | $1.23B |
| Cash at end of period | $531.6M | $558.8M | $751.3M | $600.7M | $1.86B |
| Operating cash flow | $238.5M | $362.9M | $405.5M | $307.3M | $156.3M |
| Capital expenditure | -$-93.4M | -$-118.3M | -$-101.7M | -$-96.4M | -$-152.1M |
| Free cash flow | $145.1M | $244.6M | $303.8M | $210.9M | $4.2M |
Line items
Line items
Line items
About Perrigo Company plc
Perrigo Company plc provides over-the-counter health and wellness solutions in the United States, Europe, and internationally. The company operates through Consumer Self-Care Americas and Consumer Self-Care International segments. It offers upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and oral electrolyte beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pain relievers and fever reducers; and oral care products, which include toothbrushes, toothbrush replacement heads, floss, flossers, whitening products, and toothbrush covers. The company also offers healthy lifestyle products, such as smoking cessation and well-being products; skin care products consisting of dermatological care, scar management, lice treatment, and other products for various skin conditions; women’s health products comprising feminine hygiene and contraceptives; vitamins, minerals, and supplements; and other miscellaneous self-care products. It sells its products under the Compeed, Dr. Fresh, Firefly, Good Sense, Good Start, Mederma, Nasonex, Plackers, Prevacid24HR, REACH, Rembrandt, Steripod, Opill, Solpadeine, Coldrex, Physiomer, NiQuitin, ACO, ellaOne, and Compeed brands. The company also offers contract manufacturing services. It sells its products through retail drug, supermarket, and mass merchandise chains; e-commerce stores; wholesalers; pharmacies; drug and grocery retailers; and para-pharmacies. The company was formerly known as Perrigo Company and changed its name to Perrigo Company plc in December 2013. Perrigo Company plc was founded in 1887 and is headquartered in Dublin, Ireland.
- CEO
- Albert A. Manzone
- Employees
- 8.1K
- Beta
- 0.52
Included in
Explore
Frequently asked questions
What is the intrinsic value of Perrigo Company plc (PRGO)?
Perrigo Company plc (PRGO) is currently overvalued based on the InvestorsCraft IC model — IC value is 20–50% below the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.
Is PRGO undervalued?
PRGO trades at a price of $15.94 (Nov 21, 2026): overvalued — IC value is 20–50% below the price.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.